You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Recent Advances in Dual PI3K/mTOR Inhibitors for Tumour Treatment
|
|---|---|
| Published in |
Frontiers in Pharmacology, May 2022
|
| DOI | 10.3389/fphar.2022.875372 |
| Pubmed ID | |
| Authors |
Xianbo Wu, Yihua Xu, Qi Liang, Xinwei Yang, Jianli Huang, Jie Wang, Hong Zhang, Jianyou Shi |
| Abstract |
The PI3K-Akt-mTOR pathway is a viable target for cancer treatment and can be used to treat various malignant tumours, including follicular lymphoma and breast cancer. Both enzymes, PI3K and mTOR, are critical in this pathway. Hence, in recent years, an array of inhibitors targeting these two targets have been studied, showing dual PI3K/mTOR inhibition compared with single targeting small molecule inhibitors. Inhibitors not only inhibit cell proliferation but also promote cell apoptosis. These inhibitors show high potency and little drug resistance even at low doses, suggesting that PI3K/mTOR inhibitors are promising cancer drugs. Herein, we summarised the recent research of PI3K/mTOR dual inhibitors-for example, structure-activity relationship, pharmacokinetics, and clinical practice, and briefly commented on them. Clinical Trial Registration: https://clinicaltrials.gov. |
X Demographics
The data shown below were collected from the profiles of 6 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Venezuela, Bolivarian Republic of | 1 | 17% |
| Unknown | 5 | 83% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 6 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 47 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 47 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 7 | 15% |
| Lecturer | 3 | 6% |
| Researcher | 3 | 6% |
| Other | 2 | 4% |
| Lecturer > Senior Lecturer | 2 | 4% |
| Other | 6 | 13% |
| Unknown | 24 | 51% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 7 | 15% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 11% |
| Chemistry | 4 | 9% |
| Agricultural and Biological Sciences | 2 | 4% |
| Medicine and Dentistry | 2 | 4% |
| Other | 3 | 6% |
| Unknown | 24 | 51% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 May 2022.
All research outputs
#7,755,290
of 23,577,761 outputs
Outputs from Frontiers in Pharmacology
#3,510
of 17,176 outputs
Outputs of similar age
#153,831
of 443,104 outputs
Outputs of similar age from Frontiers in Pharmacology
#164
of 1,207 outputs
Altmetric has tracked 23,577,761 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 17,176 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.0. This one has done well, scoring higher than 79% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 443,104 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 63% of its contemporaries.
We're also able to compare this research output to 1,207 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 86% of its contemporaries.